Compare TransMedics Group Inc (TMDX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Advanced Drainage Systems Inc — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Advanced Drainage Systems Inc trades at $131.78 (market cap $10.08B). The key difference: Advanced Drainage Systems Inc is far larger — about 3.3× TransMedics Group Inc's market cap, and Advanced Drainage Systems Inc pays a 0.6% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WMS | |
|---|---|---|
Market Cap | $3.06B | $10.08B |
Sector | Technology | Industrials |
52-Week High | $150.42 | $175.38 |
52-Week Low | $61.99 | $129.50 |
Enterprise Value | $3.46B | $11.68B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Advanced Drainage Systems (WMS) trades at $133.67, down 1.54% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding the $2.10 forecast. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. Analyst consensus is a Buy with a $188.20 price target, though technical indicators show selling pressure. Recent news highlights institutional buying and strong Q1 2027 results.
The outlook for WMS is mixed; strong fundamentals and analyst optimism contrast with near-term technical weakness. Investment opportunities include market share gains and acquisition synergies, while risks involve cyclical construction exposure and rising investing cash outflows. The stock's current price offers a potential upside to the consensus target, but investors should weigh execution risks against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
